NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis $1.70 -0.04 (-2.30%) Closing price 07/10/2026 04:10 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07/10/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Stereotaxis Stock (NYSEAMERICAN:STXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Stereotaxis alerts:Sign Up Key Stats Today's Range$1.64▼$1.7550-Day Range$1.62▼$2.0852-Week Range$1.59▼$3.59Volume567,751 shsAverage Volume578,051 shsMarket Capitalization$166.16 millionP/E RatioN/ADividend YieldN/APrice Target$3.88Consensus RatingBuy Company Overview Stereotaxis, Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff. The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology. Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.AI Generated. May Contain Errors. Read More Stereotaxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreSTXS MarketRank™: Stereotaxis scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingStereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialStereotaxis has a consensus price target of $3.88, representing about 127.9% upside from its current price of $1.70.Amount of Analyst CoverageStereotaxis has only been the subject of 2 research reports in the past 90 days.Read more about Stereotaxis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.20) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 12.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stereotaxis' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.19% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 6.13.Change versus previous monthShort interest in Stereotaxis has recently increased by 10.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentStereotaxis has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Stereotaxis this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have not sold or bought any company stock.Percentage Held by Insiders16.03% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STXS Stock News HeadlinesSTXS Share News TodayJuly 9 at 1:31 PM | uk.investing.comStereotaxis Completes Acquisition of RobocathJuly 9 at 8:08 AM | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 11 at 1:00 AM | Altimetry (Ad)Analysts See 124.7% Upside In Stereotaxis (STXS); Find Out WhyMay 24, 2026 | finance.yahoo.comStereotaxis Inc (STXS) Q1 2026 Earnings Call Highlights: Navigating Regulatory Wins and Revenue ...May 13, 2026 | finance.yahoo.comStereotaxis, Inc. (STXS) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comStereotaxis Reports 2026 First Quarter Financial Results & Business UpdatesMay 12, 2026 | globenewswire.comWhy Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30May 2, 2026 | finance.yahoo.comSee More Headlines STXS Stock Analysis - Frequently Asked Questions How have STXS shares performed this year? Stereotaxis' stock was trading at $2.30 at the beginning of the year. Since then, STXS shares have decreased by 26.1% and is now trading at $1.70. How were Stereotaxis' earnings last quarter? Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its quarterly earnings results on Monday, March, 9th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company earned $8.64 million during the quarter, compared to the consensus estimate of $9.24 million. Stereotaxis had a negative trailing twelve-month return on equity of 163.30% and a negative net margin of 69.50%. Read the conference call transcript. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stereotaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings3/09/2026Today7/11/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 STXS's financial health is in the Red zone, according to TradeSmith. STXS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:STXS CIK1289340 Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees130Year FoundedN/APrice Target and Rating Average Price Target for Stereotaxis$3.88 High Price Target$4.00 Low Price Target$3.50 Potential Upside/Downside+127.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.64 million Net Margins-69.50% Pretax Margin-69.50% Return on Equity-163.30% Return on Assets-30.08% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.11 Sales & Book Value Annual Sales$32.38 million Price / Sales5.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book12.14Miscellaneous Outstanding Shares97,740,000Free Float82,070,000Market Cap$166.16 million OptionableNot Optionable Beta1.34 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSEAMERICAN:STXS) was last updated on 7/11/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
